Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028093 · ClinicalTrials.gov registry record · Phase 4
Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease
A Phase 4 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT00028093 is a Phase 4 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 50 participants.
The verdict
NCT00028093, a Phase 4 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study will examine the effectiveness of pegylated interferon, or peginterferon (a long-acting form of alpha interferon) plus ribavirin in treating hepatitis C (genotype 1) infection with and without kidney disease.
Interventions
- DRUG Peginterferon alfa-2a
- DRUG Peginterferon alfa-2a with Ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2001-12 |
| Est. Completion | 2010-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028093
The ClinicalTrials.gov registry entry for NCT00028093 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Peginterferon alfa-2a is the first listed.
NCT00028093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028093 about?
NCT00028093 is a clinical study titled "Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease". This study will examine the effectiveness of pegylated interferon, or peginterferon (a long-acting form of alpha interferon) plus ribavirin in treating hepatitis C (genotype 1) infection with and without kidney disease.
What is the current status of trial NCT00028093?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2001-12. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00028093?
The interventions under investigation include: Peginterferon alfa-2a (DRUG), Peginterferon alfa-2a with Ribavirin (DRUG).
Who is sponsoring clinical trial NCT00028093?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.